0
0

Cart (0)

Home > SIL NDSRI's > Rasagiline

Rasagiline -SIL NDSRI's
Wishlist
Select options

N-Nitroso Rasagiline-D4

  • CAT NUMBER DCTI-A-274
  • CAS NUMBER NA
  • MOLECULAR FORMULA C12H8D4N2O
  • MOLECULAR WEIGHT 204.12
Select options
Wishlist
References
FAQ's

References

  1. Youdim, Moussa B. H.; Finberg, John P. M.; Levy, Ruth; Sterling, Jeffrey; Lerner, David; Berger-Paskin, Tirtsah, R-Enantiomer of N-propargyl-1-aminoindan, its preparation and pharmaceutical compositions containing it, Teva Pharmaceutical Industries Ltd., Israel and Technion Research and Development Foundation Ltd., Israel, EP436492B1, June 8, 1994
  2. Ma, Jinfei; Chen, Xiaoyan; Duan, Xiaotao; Deng, Pan; Wang, Hui; Zhong, Dafang, Validated LC-MS/MS method for quantitative determination of rasagiline in human plasma and its application to a pharmacokinetic study, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Volume: 873, Issue: 2, Pages: 203-208, 2008

Frequently Asked Questions

Yes, Rasagiline impurities can affect the drug's effectiveness as they can alter its pharmacological properties and lead to variations in therapeutic response.

Yes, Rasagiline impurities are regulated by authorities to ensure the safety and quality of the medication.

The significance of controlling Rasagiline impurities is to ensure the safety, efficacy, and quality of the medication, as impurities can potentially affect its therapeutic effectiveness and may pose health risks to patients.

Rasagiline impurities should be stored at a controlled room temperature between 2-8 °C or as indicated on the Certificate of Analysis (CoA).

Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.

Back to Top
Product has been added to your cart
jQuery(window).on('load', function() { $('input[name="productname"]').val($('.product_title').html()); });